Overlooked drugs can gain value when markets evolve, says Azurity CEO

Ron Scarboro, chief executive of Azurity Pharmaceuticals, wrote about how medicines that seemed unsuccessful can become valuable when market conditions change.

He argues that the industry often concentrates on discovering new molecules while neglecting the potential of existing compounds whose strategic worth may rise as treatment paradigms, patient expectations, and commercial models shift.

Scarboro cites the case of an oral obesity combination therapy approved in 2014. It quickly became the most‑prescribed branded anti‑obesity drug in the United States, yet its maker filed for Chapter 11 just three years later, illustrating how a once‑promising market can deteriorate.

The piece concludes that as science and technology advance, companies and investors should periodically reassess older assets, because a change in the surrounding market can turn a previously overlooked medicine into a new opportunity.